Second Line Therapy for IDH1 Mutated Acute Myeloid Leukemia
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

Second Line Therapy for IDH1 Mutated Acute Myeloid Leukemia

Sponsor: FORMA Therapeutics, Inc.

A phase 1/2 study of FT-2102 as a single agent or in combination with azacitidine or cytarabine for patients with previously treated IDH1 mutated acute myeloid leukemia.